首页 | 官方网站   微博 | 高级检索  
     

胸痹通胶囊对心肌缺血大鼠血管活性物质释放的影响
引用本文:张太国,唐可欣,赵淑梅,唐可清,田立.胸痹通胶囊对心肌缺血大鼠血管活性物质释放的影响[J].中国组织工程研究与临床康复,2005,9(31):206-207.
作者姓名:张太国  唐可欣  赵淑梅  唐可清  田立
作者单位:1. 潍坊医学院保健科,山东省,潍坊市,261042
2. 潍坊医学院生理学教研室,山东省,潍坊市,261042
3. 潍坊医学院免疫与病原生物学教研室,山东省,潍坊市,261042
4. 潍坊市中医院内科,山东省,潍坊市,261041
基金项目:潍坊市科委资助(WK02212)Supported by: Weifang Science and Technology Foundation, No. WK02212
摘    要:背景检测实验性心肌缺血大鼠的血管活性物质,探讨胸痹通胶囊的药理作用途径.目的为观察胸痹通胶囊对大鼠心肌缺血时血浆中血管活性物质释放的影响.设计完全随机分组设计,对照实验.单位潍坊医学院保健科,生理学教研室,免疫与病原生物学教研室和潍坊市中医院内科.材料实验于2003-01/2003-06在潍坊医学院生理学教研室完成.选用清洁级Wistar大鼠30只,鼠龄6~8个月,雌雄不限,将动物随机分为正常对照组、模型对照组和模型治疗组.方法1]造模前12 h,模型治疗组大鼠灌服胸痹通胶囊(组方云苓、清夏、枳实、橘红、石菖蒲、灸复花、降香、栝蒌、郁金、丹参、太子参、麦冬、远志、炒枣仁等,经加工制成每粒含生药1g的胶囊)1次,剂量2.5 g/kg,溶于4mL生理盐水中灌胃;造模后10 h再重复灌胃1次.正常对照组和模型对照组在相同时间灌服等量的生理盐水.首次给药后1 h,模型对照组和模型治疗组均按10 mg/kg的剂量皮下注射硫酸异丙基肾上腺素,制成大鼠心肌缺血动物模型.2]按北京东亚免疫技术研究所提供试剂盒说明书测定血浆内皮素、降钙素基因相关肽、6-酮-前列腺素F1α和血栓素B2.3]采用方差分析及q检验进行组间对照比较.主要观察指标各实验组大鼠血浆中血管活性物质的浓度.结果大鼠30只均进入结果分析.1]血浆血栓素B2,内皮素水平及血栓素B2/6-酮-前列腺素F1α,内皮素/降钙素基因相关肽正常对照组和模型治疗组明显低于模型对照组(q=2.99~9.87,P<0.05~0.01).2]6-酮-前列腺素F1α,降钙素基因相关肽水平正常对照组和模型治疗组明显高于模型对照组(603.3±90.6),(190.0±64.2)ng/L;(560.7±111.1),(174.9±41.4)ng/L;(380 4±705),(114.9±36.4)ng/L,q=3.88~7.64,P<0.05~0.01].结论胸痹痛胶囊可明显抑制心肌缺血时缩血管物质的异常释放,并增加扩血管物质的含量,纠正体内重要的血管活性物质血栓素B2、6-酮-前列腺素F1α、内皮素和降钙素基因相关肽含量的失衡.

关 键 词:心肌缺血  胶囊  降钙素基因相关肽  前列腺素
文章编号:1671-5926(2005)31-0206-02
修稿时间:2005年4月20日

Effect of xiongbitong capsule on releasing of vasoactive substances of rats with myocardial ischemia
Zhang Tai-guo,Tang Ke-xin,Zhao Shu-mei,Tang Ke-qing,Tian Li.Effect of xiongbitong capsule on releasing of vasoactive substances of rats with myocardial ischemia[J].Journal of Clinical Rehabilitative Tissue Engineering Research,2005,9(31):206-207.
Authors:Zhang Tai-guo  Tang Ke-xin  Zhao Shu-mei  Tang Ke-qing  Tian Li
Abstract:BACKGROUND: By detecting vasoactive substances of experimental rats with myocardial ischemia, pharmacological mechanism of xiongbitong was studied in this research.OBJECTIVE: To observe the effect of xiongbitong capsule on release of vasoactive substances of rats with myocardial ischemia.DESIGN: A completely randomized controlled study.SETTING: Department of Health, Weifang Medical College; Department of Physiology, Department of Immunity and Pathogenic Biology, Department of Internal Medicine, Weifang College of Traditional Chinese Medicine.MATERIALS: The experiment had been carried out in the Laboratory of Physiology of Weifang Medical College from January 2003 to June 2003.The cleansing grade 30 Wistar rats, 6-8 months, of either sex, were randomly divided into three groups:namely, normal control group, model control group and model group of treatment with xiongbitong capsule.METHODS: 1] At 12 hours before making model, rats of model treatment group were irrigated with xiongbitong capsule 2.5 g/kg (a capsule contents dried medicinal herbs 1 g), which consists of tuckahoe, rhizoma, immature bitter orange, exocarpium citri grandis, rhizoma acori tatarinowi, moxibustion, dalbergia wood, mongolian snakegourd, curcuma root, red sage root,root of donopsis pilosula, ilyturf root, ophiopogon, polygala root, date kernel etc., and dissolved in 4 mL physiological saline. AT ten hours after making model, they were irrigated with same dose once more. The rats of normal control group and model control group were irrigated with the same dose physiological saline at the same time. One hour after the first irrigation, the animal models of myocardial ischemia of rats of model control group and model treatment group were established by injecting vitriol isoprenaline according to 10 mg/kg subcutaneously. 2] Endothelin (ET), calcitonin generelates peptide (CGRP), 6-keto-prostaglandin Fl alpha (6-keto-PGF1α) and thromboxane B2 (TXB2) in the plasma of rats were detected according to the explanation of Institute of Beijing East Asia Immune Technique. 3] The analysis of variance and q test were used for comparing between groups.MAIN OUTCOME MEASURES: Contents of vasoactive substances in the plasma of rats in each experimental group.RESULTS: The date of all thirty rats was entered the final analysis. 1]The contents of (TXB2) and ET, TXB2/6-Keto-PGF1α, ET/CGRP: Compared with the model group, the normal control group and model treatment group reduced obviously (q=2.99-9.87, P < 0.05-0.01). 2] The contents of 6-Ke-to-PGF1α and CGRP: Compared with the model group, the normal control group and model treatment group increased obviously (603.3 ±90.6),(190.0±64.2) ng/L; (560.7±111.1), (174.9±41.4) ng/L; (380.4±705),(114.9±36.4) ng/L, q=3.88-7.64, P < 0.05-0.01].CONCLUSION: Xiongbitong capsule may suppress unusual release of vasoactive material at myocardial ischemia area obviously, increase the content of expanding the blood vessel material, and correct out-of-balance of content of important TXB2, 6-keto-PGF1α, XTB and CGRP in the body.
Keywords:
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号